8952 Schlieren, ch
+41 (44) 73347-47
Extraordinary General Meeting of Kuros Biosciences approves all resolutions
Shareholders resolved on an increase and adjustment of the authorized share capital (up to 4,000,000 registered shares with a nominal value of CHF 1.00 each) and the conditional share capital for Employee Participation (up to 2,248,389 registered shares with a nominal value of CHF 1.00 each). They also resolved an increase and adjustment of the Conditional Share Capital for bonds and similar debt instruments (up to 4,000,000 registered shares with a nominal value of CHF 1.00 each), and corresponding changes to the Articles of Incorporation.
The Extraordinary General Meeting took place at the Company’s headquarters in Schlieren. It was attended by 32 shareholders. 7,909,950 shares or 52.0% of a total of 15,203,786 shares were represented.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.